Allakos Q3 2021 Earnings Report
Key Takeaways
Allakos reported a net loss of $62.7 million in the third quarter of 2021, compared to a net loss of $42.1 million in the same period in 2020. The company ended the quarter with $505.6 million in cash, cash equivalents and marketable securities.
Presented data at ACG 2021 showing high prevalence rates of EG/EoD with systemic evaluation.
Topline data from a Phase 3 study of lirentelimab in patients with EG/EoD expected in Q4 2021 or early Q1 2022.
Topline data from a Phase 2/3 study of lirentelimab in patients with EoE expected in Q4 2021 or early Q1 2022.
Initiation of a Phase 2/3 study of subcutaneous lirentelimab in patients with EG and/or EoD expected in Q4 2021.
Allakos
Allakos
Forward Guidance
This press release contains forward-looking statements regarding Allakos' progress and business plans, the expected timing of anticipated study results and plans relating to its future clinical trials.